All In Biotech

Drug Trial Radar · NCT06303505

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

A Multicenter, First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

334

Planned (sponsor's estimate)

Start

Jun 12, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with ovarian cancer or non-small cell lung cancer (NSCLC). The primary objectives of this study are: Phase 1: To determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) or the identified dose for optimization (IDO). Phase 2a: To assess safety of TUB-040, the preliminary efficacy of TUB-040, and to identify the recommended phase II dose (RP2D) for further development of TUB-040 . Phase 2b: To determine the efficacy of TUB-040 in patients with PROC.

Conditions

  • Ovarian Cancer
  • Non-small Cell Lung Cancer

Interventions

  • TUB-040Drug

    Administered intravenous (IV) on day 1 of each 21-day treatment cycle

  • BevacizumabDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs)Time frame: First dose up to 21 days
  2. Phase 1 and 2a: Percentage of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs)Time frame: First dose date up to 30 days post last dose (Up to 3 years)
  3. Phase 2a & 2b: Overall Response Rate (ORR) by Blinded Independent Central Review (BICR)Time frame: Up to 3 years

Locations

21 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Winship Cancer Institute Emory University

    Atlanta, Georgia · Recruiting

  • Dana Farber Cancer Institute (DFCI)

    Boston, Massachusetts · Recruiting

  • START New Jersey (Astera Cancer Center)

    East Brunswick, New Jersey · Recruiting

  • Mount Sinai

    New York, New York · Recruiting

  • The Christ Hospital Physicians - Mt. Auburn

    Cincinnati, Ohio · Recruiting

  • Ohio State University CRS

    Columbus, Ohio · Recruiting

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Asante Rogue Region al Medical Center

    Medford, Oregon · Recruiting

  • START Dallas Fort Worth

    Fort Worth, Texas · Recruiting

  • NEXT Oncology Dallas

    Irving, Texas · Recruiting

  • START Mountain Region

    West Valley City, Utah · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • UZ Leuven - PPDS

    Leuven, Belgium · Recruiting

  • Charité- Universitaetsmedizin Berlin

    Berlin, Germany · Recruiting

  • University Hospital of Cologne

    Cologne, Germany · Recruiting

  • ARENSIA Exploratory Medicine, LLC

    Cluj-Napoca, Romania · Recruiting

  • Clínica Universidad de Navarra - Madrid

    Madrid, Spain · Recruiting

  • NEXT Madrid, University Hospital Quironsalud Madrid

    Madrid, Spain · Recruiting

  • ARENSIA Exploratory Medicine, LLC

    Kyiv, Ukraine · Active not recruiting

  • Guy's Hospital

    London, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.